MedPath

a clinical trial to study the effects of periodontal therapy in Chronic Obstructive Pulmonary Disorder (COPD) patients.

Active, not recruiting
Conditions
chronic obstructive pulmonary disorder patients having chronic periodontitis
Registration Number
CTRI/2014/01/004296
Brief Summary

This study is a non randomized, single blind, parallel group trail to study the effectiveness of periodontal therapy in patients with Chronic Obstructive Pulmonary Disorder having chronic periodontitis. The primary outcome measures will be quality of life using St George’s Respiratory Questionnaire at 6 months. The secondary outcomes will be exacerbation rates, lung function tests and lung inflammation at 6 months.

Detailed Description

Not available

Recruitment & Eligibility

Status
Closed to Recruitment of Participants
Sex
Male
Target Recruitment
40
Inclusion Criteria
  • 1.COPD patients having chronic periodontitis.
  • 2.Presence of atleast 20 teeth in the mouth.
  • 3.Patients willing to quit smoking.
Exclusion Criteria
  • 1)Subjects having immunocompromised diseases and other debilitating diseases like asthma, epilepsy, diabetes mellitus, renal failure, hepatic diseases, cardiovascular disease, pneumonia.
  • 2)Non ambulatory COPD patients.
  • 3)Severe and very severe COPD patients.
  • 4)Unwilling patients.
  • 5)Patients who do not take regular medication for COPD.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
quality of life of COPD patientsbaseline and 6 months
Secondary Outcome Measures
NameTimeMethod
lung function, exacerbation rates and inflammatory mediatorsbaseline and 6 months

Trial Locations

Locations (1)

Dr D.Y. Patil Dental College and Hospital

🇮🇳

Pune, MAHARASHTRA, India

Dr D.Y. Patil Dental College and Hospital
🇮🇳Pune, MAHARASHTRA, India
Dr Khushboo Thakkar
Principal investigator
9860248814
khush.arien@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.